1. In Vivo
  2. >>Business Strategy

The Truly Transformational Potential Of AI Relies On The Data

 
• By David Wild

Executives from several AI-focused biotechs emphasize that generating a truly innovative medicine, as opposed to a me-too drug, depends not just on the quantity, but on the quality of data used by the algorithm.    

Business development idea and developing industry success through creative invention as a light bulb evolving to a gear shape as a 3D illustration.

“The power of AI isn’t about making drugs faster,” said Abraham Heifets, CEO of Atomwise, Inc., an AI-enabled drug discovery company headquartered in San Francisco. “If you approach a big pharma and you are going to be fifth-in-class and undifferentiated, and through the power of AI, we can make you fourth-in-class and undifferentiated, that's a failure from a business point of view, it's a failure strategically and it's a failure for patients.”

However, the bar for AI seems to be low. Heifets said he has far more conversations around the ability of...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Business Strategy

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.